Martin Roessner

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Johann S. de Bono, Stéphane Oudard, Mustafa Özgüroğlu et al. · The Lancet · 2010 · 3.3K citations

Urology, Medicine, Pharmacology +7

Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between Prostate-Specific Antigen, Pain, and Quality of Life Response and Survival in the TAX-327 Study

Dominik Berthold, Gregory R. Pond, Martin Roessner et al. · Clinical Cancer Research · 2008 · 206 citations

Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation

Marshall R. Posner, Charles M. Norris, Lori J. Wirth et al. · Annals of Oncology · 2009 · 148 citations · Full text

Tax 324, Surgical Oncology, Medicine +10

Sample size considerations for Japanese patients in a multi‐regional trial based on MHLW guidance

Hui Quan, Peng‐Liang Zhao, Ji Zhang et al. · Pharmaceutical Statistics · 2009 · 83 citations

Patient Selection, Clinical Endpoint, Pharmacotherapy +19

Reliability of treadmill testing in peripheral arterial disease: a comparison of a constant load with a graded load treadmill protocol

Karl‐Heinz Labs, Mark R. Nehler, Martin Roessner et al. · Vascular Medicine · 1999 · 68 citations